ArticleESMO gastrointestinal oncology2026
A pragmatic phase II trial evaluating treatment strategies using immune checkpoint inhibitors for metastatic esophageal cancer patients with severe dysphagia.
Y Nagata et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.